Clinical trial · Expanded Access
Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis
Post-Trial Access for Guselkumab in Patients With Familial Adenomatous Polyposis Who Are Experiencing Clinical Benefit After Completing 48 Weeks of Treatment in CNTO1959COR1001
NCT04948398CI-TRIAL-00085408no longer availableClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this post-trial access (PTA) program is to provide guselkumab to participants with Familial Adenomatous Polyposis (FAP) who are experiencing clinical benefit after completing 48 weeks of treatment in Study CNTO1959COR1001.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenomatous Polyposis Coli | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Guselkumab | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
Show eligibility record
- sex
- null
- stdAges
- CHILD
- ADULT
- OLDER_ADULT
- criteria
- null
- maximumAge
- null
- minimumAge
- null
- healthyVolunteers
- null
References
Publications (0)
Data not yet available
No reference posted for this study.